Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Fiche publication
Date publication
janvier 2015
Journal
Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARBAR Christian, Pr BENSUSSAN Armand
Tous les auteurs :
Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H
Lien Pubmed
Résumé
Neoadjuvant chemotherapy (NACT) allows for a more frequent use of breast-conservative surgery; it is also an in vivo model of individual tumor sensitivity which permits to determine new prognostic factors to personalize the therapeutic approach.
Mots clés
Adult, Aged, Aged, 80 and over, Anthracyclines, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Breast Neoplasms, drug therapy, Carcinoma, Ductal, Breast, drug therapy, Chemotherapy, Adjuvant, Confounding Factors (Epidemiology), Cyclophosphamide, administration & dosage, Disease-Free Survival, Drug Administration Schedule, Epirubicin, administration & dosage, Female, Fluorouracil, administration & dosage, Follow-Up Studies, France, epidemiology, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoadjuvant Therapy, methods, Neoplasm Staging, Neoplasm, Residual, epidemiology, Prognosis, Retrospective Studies, Risk Factors, Taxoids, administration & dosage, Treatment Outcome
Référence
Oncology. 2015 ;88(5):261-72